Complete Versus Culprit-Only Revascularization to Treat Multivessel Disease After Early PCI for STEMI (COMPLETE)
Source: View publication →
The COMPLETE trial demonstrated that in patients with STEMI and multivessel coronary artery disease, a strategy of staged complete revascularization significantly reduces the risk of cardiovascular death or myocardial infarction compared to a culprit-lesion-only approach.
Key Findings
Study Design
Study Limitations
Clinical Significance
The COMPLETE trial provides high-quality evidence to shift clinical practice from a 'culprit-only' strategy to one of complete, staged revascularization for stable nonculprit lesions in patients with STEMI and multivessel coronary disease, providing a clear benefit for hard cardiovascular outcomes.
Historical Context
Prior to the COMPLETE trial, the management of nonculprit lesions in STEMI patients with multivessel disease was controversial, with previous smaller trials yielding conflicting results and primarily driving reductions in revascularization rather than hard endpoints like death or MI; COMPLETE was the largest trial to definitively establish the superiority of complete revascularization.
Guided Discussion
High-yield insights from every perspective
In the context of the COMPLETE trial, what is the pathophysiological distinction between a 'culprit' lesion and a 'non-culprit' lesion in a patient presenting with an acute STEMI?
Key Response
A culprit lesion is the site of acute plaque rupture or erosion leading to total or subtotal coronary occlusion and subsequent myocardial infarction. Non-culprit lesions represent stable but significant atherosclerotic obstructions in other coronary arteries. Understanding this distinction is foundational for clinical reasoning, as it defines the difference between treating the immediate life-threatening event and managing the patient's overall burden of coronary artery disease.
The COMPLETE trial suggests a benefit for staged revascularization. How should a clinician decide the optimal timing for treating non-culprit lesions based on this study's protocol and results?
Key Response
In COMPLETE, non-culprit PCI was performed either during the index hospitalization or after discharge (median 1 day for the former, 19 days for the latter). The study showed that the benefit of complete revascularization was consistent regardless of whether the staged procedure occurred during the index stay or within 45 days of discharge, allowing for clinical flexibility based on patient stability and logistical factors.
How do the findings of the COMPLETE trial integrate with the results of the CULPRIT-SHOCK trial when managing a patient with multivessel disease and STEMI complicated by cardiogenic shock?
Key Response
It is critical to differentiate the stable STEMI population in COMPLETE from the shock population in CULPRIT-SHOCK. While COMPLETE supports routine staged complete revascularization for stable patients, CULPRIT-SHOCK demonstrated that immediate multivessel PCI in the setting of cardiogenic shock increases the risk of death or renal failure. Therefore, the 'complete' strategy should generally be staged and reserved for hemodynamically stable patients.
Considering the COMPLETE trial demonstrated a significant reduction in MI but not a statistically significant reduction in all-cause mortality, how do you incorporate these findings into your shared decision-making process for an elderly patient with significant comorbidities?
Key Response
The benefit in COMPLETE was driven primarily by a reduction in new myocardial infarctions (hazard ratio 0.68). In an elderly patient with high frailty or bleeding risk, the attending must weigh the 'preventive' benefit of avoiding a future MI against the procedural risks (stroke, contrast nephropathy, bleeding) of additional PCI, recognizing that the absolute mortality benefit may be minimal in patients with limited life expectancy.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The COMPLETE trial utilized a composite primary endpoint of cardiovascular death or myocardial infarction. From a methodological standpoint, how does the inclusion of 'ischemia-driven revascularization' in the secondary composite endpoint affect the interpretation of the trial's 'hard' clinical outcomes?
Key Response
Including soft endpoints like revascularization often inflates the treatment effect size because these endpoints are more frequent and prone to physician bias (especially in open-label trials). By separating the hard endpoint (CV death/MI) from the soft endpoint (ischemia-driven revascularization), COMPLETE provided robust evidence that the benefit extends to actual muscle-sparing outcomes rather than just reducing the physician's urge to fix known narrowings.
As a reviewer, what concerns would you raise regarding the potential for 'detection bias' in the COMPLETE trial, and how did the study design attempt to mitigate the risk of unblinded clinicians over-reporting events in the culprit-only group?
Key Response
Because the trial was open-label, clinicians knew which patients had residual disease. This could lead to a lower threshold for diagnosing MI or performing revascularization in the culprit-only group. To mitigate this, the trial used a blinded independent clinical events committee to adjudicate all suspected outcomes based on objective criteria (troponin levels, ECG changes), which is a critical standard for high-quality cardiovascular trials.
Following the COMPLETE trial, should the Class of Recommendation for non-culprit PCI in STEMI be upgraded from IIa to I in the ACC/AHA guidelines, and what specific level of evidence should be assigned?
Key Response
Prior to COMPLETE, guidelines (e.g., 2015 ACC/AHA update) gave a Class IIb or IIa recommendation for non-culprit PCI. Given that COMPLETE is a large-scale (4,000+ patients), multi-center, randomized controlled trial showing a clear reduction in hard endpoints (MI), it provides the 'Level A' evidence necessary to support a Class I recommendation (strong recommendation) for staged complete revascularization in stable STEMI patients with multivessel disease.
Clinical Landscape
Noteworthy Related Trials
PRAMI Trial
Tested
Preventive PCI of non-culprit stenoses
Population
Patients with STEMI and multivessel coronary artery disease
Comparator
Culprit-only PCI
Endpoint
Composite of cardiac death, nonfatal MI, or refractory angina
CvLPRIT Trial
Tested
Complete revascularization during the index hospital admission
Population
Patients with STEMI and multivessel disease
Comparator
Culprit-only revascularization
Endpoint
Composite of all-cause mortality, recurrent MI, heart failure, and ischemia-driven revascularization at 12 months
DANAMI-3-PRIMULTI Trial
Tested
FFR-guided complete revascularization
Population
Patients with STEMI and multivessel disease with non-culprit stenosis
Comparator
Conservative treatment (culprit-only)
Endpoint
Composite of cardiac death, nonfatal MI, or ischemia-driven revascularization of non-culprit lesions
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis